Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients
Clinical Immunology · 2025-11 · 280 · 110557
DOI: 10.1016/j.clim.2025.110557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2025-11. Verfasst von Katarina Mirjačić Martinović und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia. Hauptthemen laut MEDLINE: Melanoma, Killer Cells, Natural, Antibodies, Monoclonal, Humanized, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Republic of Serbia Ministry of Education Science and Technological Development.
Abstract (Originalsprache)
Therapeutical blockade of programmed cell death protein 1 (PD-1) axis may enhance anti-tumor immunity and especially natural killer (NK) cells activity. In 32 BRAF wild type (wt) metastatic melanoma (MM) patients before and after every 12 weeks of therapy with PD-1 inhibitor, Pembrolizumab, we analyzed the percentage of T cell subsets, NK cells and CD14+HLA-DR- monocytes, the expression of CD107a degranulation marker, activating NKG2D, NKp46, DNAM-1 and inhibitory CD158a receptors on NK cells by Flow cytometry, until one year or disease progression (DP). The patients with disease control (non-DP patients) had significant increase in lymphocyte count, percentage of NK cells, increased expression of CD107a, NKG2D, NKp46, but decreased CD158a on NK cells during Pembrolizumab therapy compared to pretherapy values. Patients with DP had increased neutrophil number, increased percentage of immunosuppressive CD14+HLA-DR- monocytes, as well as increased CD158a expression on NK cells. In MM patients with disease control, contrary to DP patients blocking of PD-1 inhibitory molecule may increase NK cell cytotoxicity through enhancement of NK cell degranulation and activating receptor expression. Therefore, our findings show that NK cells and their receptors in MM patients may be potential biomarkers of response to Pembrolizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
- Department of Medical Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
- Faculty of Medical Sciences, University of Kragujevac, P.BOX 124, 34 000 Kragujevac, Serbia. Electronic address: jurisicvladimir@gmail.com.
Förderung
- Republic of Serbia Ministry of Education Science and Technological Development
Zitieren
APA
Martinović, K. M., Vuletić, A., Miletić, N. T., Nedeljković, M., Matković, S., & Jurišić, V. (2025). Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients. Clinical Immunology, 280, 110557. https://doi.org/10.1016/j.clim.2025.110557
Vancouver
Martinović KM, Vuletić A, Miletić NT, Nedeljković M, Matković S, Jurišić V. Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients. Clinical Immunology. 2025;280:110557. doi:10.1016/j.clim.2025.110557
BibTeX
@article{Martinovi2025,
author = {Martinović, Katarina Mirjačić and Vuletić, Ana and Miletić, Nevena Tišma and Nedeljković, Milica and Matković, Suzana and Jurišić, Vladimir},
title = {Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients},
journal = {Clinical Immunology},
year = {2025},
volume = {280},
pages = {110557},
doi = {10.1016/j.clim.2025.110557}
}
EUVIMED